Alzamend Neuro IncALZN
▲ PositiveRegulationrelevance
Alzamend Neuro regained compliance with Nasdaq's equity listing rule, resolving its listing deficiency.
Impact on stocks 1
Biotech & Genomic Medicine
Alzamend Neuro IncAlzamend Neuro has regained compliance with Nasdaq listing standards, according to a notification letter from Nasdaq dated September 14, 2026. The notice informed the company that it now complies with the equity rule, and Nasdaq stated the matter is now closed. The notification resolves the listing deficiency for the biopharmaceutical company, whose shares trade under the ticker ALZN.
Alzamend Neuro IncAlzamend Neuro regained compliance with Nasdaq's equity listing rule, resolving its listing deficiency.